{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-24-000049","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.262360+00:00","generated_at":"2026-06-01T04:06:48.075176+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Salarius reports 43% ORR for seclidemstat combo in MDS/CMML at EHA 2024","bullets":["Seclidemstat + azacitidine: 43% overall response rate (6/14 evaluable) in higher-risk MDS/CMML patients who failed HMA therapy.","Median overall survival 18.5 months (95% CI 6.1-30.9) vs typical 4-6 months after HMA failure; median event-free survival 7.2 months.","Phase 1/2 dose-escalation enrolling Cohort 5 (750mg BID) and planned Cohort 6 (900mg BID); MTD not yet reached.","Dose-limiting toxicity observed in 1 patient at 750mg BID; cohort expanded per protocol; adverse events deemed manageable.","Data presented by MD Anderson investigator at European Hematology Association meeting June 13-16, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-24-000049","json":"https://secwatch.observer/filing/0001615219-24-000049.json","markdown":"https://secwatch.observer/filing/0001615219-24-000049.md","text":"https://secwatch.observer/filing/0001615219-24-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521924000049/0001615219-24-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521924000049/flks-20240617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:06:48.075176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}